Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)
Blood (2013)
  • Farhad Ravandi, University of Texas MD Anderson Cancer Center
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Jae H Park, Memorial Sloan Kettering Cancer Center
  • Dan Douer, Memorial Sloan Kettering Cancer Center
  • Elihu H. Estey, Fred Hutchinson Cancer Research Center
  • Hagop M Kantarjian, University of Texas MD Anderson Cancer Center
  • Dragan Cicic
  • David A. Scheinberg, Memorial Sloan Kettering Cancer Center
Link
Disciplines
Publication Date
November 15, 2013
Citation Information
Farhad Ravandi, John M. Pagel, Jae H Park, Dan Douer, et al.. "Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)" Blood Vol. 122 Iss. 21 (2013) p. 1460 - 1460
Available at: http://works.bepress.com/john-pagel/113/